Literature DB >> 19267218

Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation.

Zheng Tianhu1, Zhao Shiguang, Liu Xinghan.   

Abstract

Malignant glioma is resistant to the induction of apoptosis, resulting in a subsequent failure of chemotherapy in clinical treatment strategies. Downregulation of bcl-2 and bcl-xl expression in glioblastoma cells can induce apoptosis. BH3-only proteins, which include Bmf, are essential initiators of stress-induced cell death and apoptosis. Whether PS-341 regulates expression of BH3-only proteins in glioblastoma cells during the procedure of apoptosis is unclear. This study was designed to investigate the effects of PS-341 on glioma cell death and its possible signaling pathway. Our results demonstrate that Bmf is upregulated by PS-341 in A172 and T98G cells, and Bmf has a crucial role in PS-341-mediated cell death. In addition, we found that expression of Bmf is regulated by JNK phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267218     DOI: 10.1007/s11033-009-9491-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

Review 1.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  The Bcl-2 family: roles in cell survival and oncogenesis.

Authors:  Suzanne Cory; David C S Huang; Jerry M Adams
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

3.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

4.  Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction.

Authors:  K Breitschopf; A M Zeiher; S Dimmeler
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

5.  Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.

Authors:  Bridget N Fahy; Michael G Schlieman; Melinda M Mortenson; Subbulakshmi Virudachalam; Richard J Bold
Journal:  Cancer Chemother Pharmacol       Date:  2005-03-25       Impact factor: 3.333

Review 6.  Proteasome inhibition: a new strategy in cancer treatment.

Authors:  J Adams; V J Palombella; P J Elliott
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

7.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

Authors:  B Li; Q P Dou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

8.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authors:  Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.

Authors:  Simon A Williams; David J McConkey
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

10.  Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.

Authors:  Jiabin An; Yiping Sun; Myrna Fisher; Matthew B Rettig
Journal:  Mol Cancer Ther       Date:  2004-06       Impact factor: 6.261

View more
  8 in total

1.  Induction of cytotoxicity by photoexcitation of TiO2 can prolong survival in glioma-bearing mice.

Authors:  Chao Wang; Shouqiang Cao; Xinxin Tie; Bo Qiu; Anhua Wu; Zhihong Zheng
Journal:  Mol Biol Rep       Date:  2010-03-30       Impact factor: 2.316

2.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Authors:  Thibault Dupont; Shao Ning Yang; Jayeshkumar Patel; Katerina Hatzi; Alka Malik; Wayne Tam; Peter Martin; John Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Oncotarget       Date:  2016-01-19

3.  Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Nikolaos E Stathakis; George K Koukoulis; Christos N Papandreou
Journal:  Cell Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.046

4.  Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Christina D Befani; Panagiotis Liakos; Christos N Papandreou
Journal:  Invest New Drugs       Date:  2013-05-05       Impact factor: 3.850

Review 5.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

6.  DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis.

Authors:  Lan Shao; Jörg J Goronzy; Cornelia M Weyand
Journal:  EMBO Mol Med       Date:  2010-10       Impact factor: 12.137

7.  RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression.

Authors:  Feng Xu; Tian Xia; Qi-Tong Xu; Xu Zhang; Yu-Zhou Huang; Xi Sun; Liang Shi; Xu-Jie Zhou; Ji-Fu Wei; Qiang Ding
Journal:  Int J Biol Sci       Date:  2022-02-07       Impact factor: 6.580

8.  Bmf upregulation through the AMP-activated protein kinase pathway may protect the brain from seizure-induced cell death.

Authors:  C Moran; A Sanz-Rodriguez; A Jimenez-Pacheco; J Martinez-Villareal; R C McKiernan; E M Jimenez-Mateos; C Mooney; I Woods; J H M Prehn; D C Henshall; T Engel
Journal:  Cell Death Dis       Date:  2013-04-25       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.